Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | SDHA | P31040 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3526323 | 1.00 | F10 (0.47) | F10MAOBPTGS1SDHALMNA | |
| SCHEMBL3519820 | 0.93 | MAOB (0.48) | F10MAOBPTGS1SDHALMNA | |
| SCHEMBL3519815 | 0.93 | MAOB (0.48) | F10MAOBPTGS1SDHALMNA | |
| SCHEMBL3519969 | 0.92 | MAOB (0.48) | F10MAOBPTGS1SDHALMNA | |
| SCHEMBL3519964 | 0.92 | MAOB (0.48) | F10MAOBPTGS1SDHALMNA | |
| SCHEMBL3526429 | 0.91 | MAOB (0.47) | F10MAOBMAOA | |
| SCHEMBL3526434 | 0.91 | MAOB (0.47) | F10MAOBMAOA | |
| SCHEMBL3522338 | 0.90 | MAOB (0.44) | F10MAOBPTGS1SDHALMNA | |
| SCHEMBL3519113 | 0.90 | MAOB (0.46) | F10MAOBPTGS1SDHALMNA | |
| SCHEMBL3519116 | 0.90 | MAOB (0.46) | F10MAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | claimed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | claimed |
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | disclosed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192275-A1 | Novel antimycobacterial compounds | MDH1, IMMT, MLYCD | F10 4391/4885MAOB 2127/4885PTGS1 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.